Docosahexaenoic Acid and Folic Acid: study protocols
12 study groups took Docosahexaenoic Acid together with Folic Acid. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Docosahexaenoic Acid
12 study groups in 10 studies say how much Docosahexaenoic Acid participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mg to 1 g and 1 g to 2.5 g, 33% of 12 study groups each.
| Daily dose | Study groups |
|---|---|
| 100 mg or less | 1 |
| 100 mg to 250 mg | 2 |
| 250 mg to 500 mg | 1 |
| 500 mg to 1 g | 4 |
| 1 g to 2.5 g | 4 |
Dose per serving from research: Folic Acid
11 study groups in 9 studies say how much Folic Acid participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mcg to 1 mg, 55% of 11 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mcg to 500 mcg | 5 |
| 500 mcg to 1 mg | 6 |
Commonly used together
9 of 12 study groups took Docosahexaenoic Acid and Folic Acid with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Choline | 5 |
| Vitamin B12 | 5 |
| Vitamin B6 | 4 |
| Vitamin C | 4 |
| Omega-3 Fatty Acids | 3 |
12 study groups
| Study | ||||
|---|---|---|---|---|
| Cognitive Benefits of Folic Acid, Docosahexaenoic Acid, and a Combination of Both Nutrients in Mild Cognitive Impairment: Possible Alterations through Mitochondrial Function and DNA Damage 2024 · FA + DHA · Adults aged 60 years and older with mild cognitive impairment | 800 mg | 800 mcg | 1 year | 70 |
| Effect of folic acid combined with docosahexaenoic acid intervention on mild cognitive impairment in elderly: a randomized double-blind, placebo-controlled trial 2021 · FA + DHA · Elderly people with mild cognitive impairment (MCI); age range and sex not specified | 800 mg | 800 mcg | 26 weeks | — |
| Effects of Folic Acid Combined with DHA Supplementation on Cognitive Function and Amyloid-β-Related Biomarkers in Older Adults with Mild Cognitive Impairment by a Randomized, Double Blind, Placebo-Controlled Trial 2021 · folic acid + DHA · Adults aged over 60 years with mild cognitive impairment | 800 mg | 800 mcg | 26 weeks | — |
| A High Omega-3 Fatty Acid Multinutrient Supplement Benefits Cognition and Mobility in Older Women: A Randomized, Double-blind, Placebo-controlled Pilot Study 2016 · Efalex Active 50+ intervention · Women aged 60 years and older, community-dwelling and able to walk at least 50 m and negotiate stairs independently; nonacutely ill | 1 g | — | 24 weeks | 15 |
| Reproductive state and choline intake influence enrichment of plasma lysophosphatidylcholine-DHA: a post hoc analysis of a controlled feeding trial 2019 · 930 mg choline per day group · Healthy non-pregnant, third-trimester pregnant, and lactating women; reproductive groups were included in the analysis | 200 mg | 600 mcg | 12 weeks | — |
| Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial 2007 · FO with MTHF · Pregnant women from gestation week 22 until delivery | 500 mg | 400 mcg | — | — |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active group (RCT1, RCT2 and RCT3) · Men and women aged 50 years or older with mild or mild-to-moderate Alzheimer's disease; RCT3 participants were on stable approved Alzheimer's medication, while RCT1 and RCT2 participants were drug-free for Alzheimer's medication. | 1.2 g | 400 mcg | 24 weeks | 501 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active product during open-label extension (OLE) · Men and women aged 50 years or older with mild Alzheimer's disease who completed RCT2. | 1.2 g | 400 mcg | 24 weeks | 201 |
| Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial 2020 · DHA treatment arm · Cognitively unimpaired men and women aged 55 years and older with a first-degree family history of dementia | 2.15 g | 800 mcg | 26 weeks | 18 |
| A Mixed Flavonoid-Fish Oil Supplement Induces Immune-Enhancing and Anti-Inflammatory Transcriptomic Changes in Adult Obese and Overweight Women-A Randomized Controlled Trial 2016 · Q-Mix · Women aged 40–70 years who were overweight or obese (BMI ≥25 kg/m²), without the listed major diseases | 90 mg | 400 mcg | 10 weeks | 24 |
| The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial 2017 · Test product (Souvenaid/Fortasyn Connect) · Adults aged 50 years or older with mild probable or possible Alzheimer’s disease | 1.2 g | 400 mcg | 4 weeks | 16 |
| Reproductive state and choline intake influence enrichment of plasma lysophosphatidylcholine-DHA: a post hoc analysis of a controlled feeding trial 2019 · 480 mg choline per day group · Healthy non-pregnant, third-trimester pregnant, and lactating women; reproductive groups were included in the analysis | 200 mg | 600 mcg | 12 weeks | — |